Fig. 3
Analysis of tumor infiltrating lymphocytes in SOMV-9RE7 treated TC-1 tumor-bearing mouse model. A Treatment schedule of C57BL/6 mice inoculated with 1 × 105 TC-1 cells s.c. and treatments are given on day 14 for three doses. Tumor and spleen from each group are harvested on day 30. B Tumor weight of each treatment group after harvestation. Treated tumors are processed and isolated for mononuclear cells. Total TIL populations are identified by staining for APC-A700-conjugated anti-mouse CD45 and BV421-conjugated anti-mouse CD3 antibodies. Representative flow cytometry images show C CD45+ and CD3+ positive lymphocyte population and D bar graph analysis of CD45+ and CD3+ TIL percentages of each treatment. E CD8+ T cell subpopulation in CD3 + /CD45 + cells are identified with PE-Cy5-conjugated anti-mouse CD8 antibody and F bar graph analysis of CD8+ TIL population. Then, PE-conjugated HPV16 E7 tetramer are used to quantify E7-specific TIL with G gating strategy for E7 positive cytotoxic T cells and H bar graph analysis of E7 percentage. G E7-specific effector T cell functionality is determined by intracellular staining with BV650-conjugated IFNγ antibody, and J calculation of IFNγ expression in each group